Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
45 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H2 2016', provides in depth analysis on Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted pipeline therapeutics. The report provides comprehensive information on the Protein Phosphatase 2A (PP2A or EC 3.1.3.16), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - The report reviews Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics and enlists all their major and minor projects - The report assesses Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Protein Phosphatase 2A (PP2A or EC 3.1.3.16) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Overview 6 Therapeutics Development 7 Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Products under Development by Stage of Development 7 Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Products under Development by Therapy Area 8 Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Products under Development by Indication 9 Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Products under Development by Companies 13 Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Therapeutics Assessment 15 Assessment by Monotherapy/Combination Products 15 Assessment by Mechanism of Action 16 Assessment by Route of Administration 18 Assessment by Molecule Type 20 Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Companies Involved in Therapeutics Development 21 Ampio Pharmaceuticals, Inc. 21 Bristol-Myers Squibb Company 22 Cyano Biotech GmbH 23 Lixte Biotechnology Holdings, Inc. 24 Signum Biosciences, Inc. 25 Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Drug Profiles 26 Drugs to Activate PP2A for Oncology - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 DT-1154 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 LB-100 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 NCE-001 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Small Molecules to Activate PP2A for Parkinson Disease and Alzheimer's Disease - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Small Molecules to Inhibit PP1 and PP2A for Oncology - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 VEL-015 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Dormant Projects 36 Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Featured News & Press Releases 37 Feb 03, 2016: Lixte Biotechnology Holdings Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression 37 Nov 06, 2015: Lixte Biotechnology Holdings Announces That Its Novel Protein Phosphatase 2A Inhibitor Is Associated With Stabilization Of Several Types Of Cancer Without Dose-Limiting Toxicity 37 Sep 17, 2015: Lixte Biotechnology Holdings Engages BioPharmaWorks To Enhance Development Of Its Pipeline Of Novel Compounds 38 Feb 25, 2015: Lixte Biotechnology's Lead Compound Reported To Be Active Against Hematologic Cancers In Pre-Clinical Studies 38 Jan 23, 2015: Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 39 Nov 06, 2014: Lixte's LB-100 Selected as One of Informa and Kantar Health's 2014 Top 10 Most Interesting Oncology Projects to Watch 39 Jun 18, 2014: Lixte's Lead Compound LB-100 Reported To Enhance Chemotherapy Effectiveness In Animal Models Of Liver Cancer 40 Apr 25, 2013: Lixte Biotechnology Initiates Phase I Trial Of Its Lead Anti-Cancer Compound LB-100 41 Jul 31, 2012: Lixte Biotechnology Announces Increased Funding And FDA Allowance To Conduct Phase I Trial Of LB-100 41 Jul 16, 2012: Ampio Pharma Advances NCE001 Cancer Drug Into Preclinical Development 41 May 01, 2012: Lixte Submits Investigational New Drug Application To FDA For Approval Of Clinical Trial Of LB-100 42 Sep 22, 2011: Lixte Biotechnology Receives US Patent For LB-100 42 Oct 05, 2010: Lixte Collaborates With NCI For Clinical Evaluation Of LB-100 43 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 44 Disclaimer 45
List of Tables
Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Early Stage Products, H2 2016 12 Number of Products under Development by Companies, H2 2016 13 Products under Development by Companies, H2 2016 14 Assessment by Monotherapy/Combination Products, H2 2016 15 Number of Products by Stage and Mechanism of Action, H2 2016 17 Number of Products by Stage and Route of Administration, H2 2016 19 Number of Products by Stage and Molecule Type, H2 2016 20 Pipeline by Ampio Pharmaceuticals, Inc., H2 2016 21 Pipeline by Bristol-Myers Squibb Company, H2 2016 22 Pipeline by Cyano Biotech GmbH, H2 2016 23 Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016 24 Pipeline by Signum Biosciences, Inc., H2 2016 25 Dormant Projects, H2 2016 36
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
